Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study for the evaluation of personalized sVCD-sVTD sequential therapy using VES-13 for newly diagnosed transplant-ineligible multiple myeloma

Next Previous
X
Search
Trial Profile

Phase II study for the evaluation of personalized sVCD-sVTD sequential therapy using VES-13 for newly diagnosed transplant-ineligible multiple myeloma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Aug 2022 Status changed from recruiting to completed.
    • 01 Nov 2021 Results (n=51; between July 2013 and Jun 2016) assessing the efficacy and safety of two sequential triplet regimens (VCD-VTD) to maximize the response rates and minimize potential toxicities in frail elderly multiple myeloma patients, published in the Annals of Hematology
    • 12 Dec 2017 Results (n=47) assessing safety and efficacy of two sequential triplet regimens to maximise the response rates and minimise potential toxicities for elderly frail multiple myeloma patients, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top